Form 4 Filing for Miralles Gines Diego

This filing details transactions made by Miralles Gines Diego, President & Head of R&D at Artiva Biotherapeutics, Inc. On May 18, 2026, Diego acquired 77,500 shares of Common Stock under the 2025 Inducement Plan, with a transaction value of $0. This acquisition is marked as direct ownership. Additionally, Diego was granted an employee stock option to buy 232,500 shares of Common Stock under the same plan, also with a transaction value of $0. The stock option vests starting May 15, 2027, with the remainder vesting monthly over the subsequent 36 months. The option has an exercise price of $9.22 and expires on May 17, 2036. The filing also includes a limited power of attorney authorizing specific individuals to execute Section 16(a) filings on behalf of Diego.